

Dockets Management Branch (HFA-305)
Division of Management Systems and Policy
Office of Human Resources and Management Services
Food and Drug Administration
5603 Fishers Lane, Room 1061
Rockville, MD 20852

2655 '00 APR 20 110 :29

Re: Docket No. 99N-4491, FDA's Enforcement Priorities for Single-Use Devices Reprocessed by Third Parties and Hospitals and Reprocessing and Reuse of Single-Use Devices: Review Prioritization Scheme

Dear Ladies and Gentlemen:

We are writing in response to the FDA's two draft guidance documents: Enforcement Priorities for Single-Use Devices Reprocessed by Third Parties and Hospitals and Reprocessing and Re-use of Single-Use Devices: Review Priorities Scheme. As professionals in the infection control and sterile processing field, we belong to a community of professionals who have been instrumental in the development of safe and effective techniques for reprocessing medical devices. This issue is of great importance to our profession and is critical to the delivery of health care.

We are very encouraged by the FDA's decision to take action on this issue to ensure and enhance patient safety. The FDA's risk-based categorization scheme is a sound approach to regulatory oversight. Factors such as risk of infection and device performance are critical in determining whether or not reprocessing is appropriate, safe and effective. We would like to take this opportunity to respond to specific issues raised in the draft documents, as follows:

We applaud FDA for recommending that opened but unused medical devices be exempt from the regulatory guidance. There is no scientific evidence that would establish a public health risk with the reprocessing of these devices. Since they have not, by definition, been previously used on a patient, the reprocessing of these devices do not raise the same level of concern as the reprocessing of devices that have been used on a patient. In addition to exempting opened but unused devices, the FDA should require Original Manufacturers(OEMs) to provide special sterilization instructions as part of the labeling requirement to ensure that the proper method of sterilization is used on those devices whose sterility may be breached and would require re-sterilization.

Exempting non-acute facilities such as ambulatory care centers, clinics, and physicians offices from regulatory guidance is counter-productive to the FDA's efforts to ensure and enhance patient safety associated with the re-use of SUD's. These health care facilities often times lack the necessary resources and protocols to ensure safe and effective reprocessing of single-use items. We strongly encourage the FDA to phase-in enforcement of the guidelines for all health care facilities that reprocess, not just hospitals.

We urge the FDA to seek uniformity from OEM's in the process and manner in which devices are labeled. There are no standards in place which guide multi-use vs. single-use labeling. An OEM should not be permitted to label a device for single-use if it is aware of safe and effective reprocessing and sterilization procedures. The device label should include the number of times the device will perform without failure as validated by the OEM. The release of FAD's final guidance documents should be delayed until the FDA addresses this labeling issue.

Furthermore, if hospitals and third party reprocessors are expected to utilize the flow chart as outlined in the Review Prioritization Scheme, the materials, coatings and components of a device must be known. And finally, in all cases, the OEMs should be required to provide instructions for acceptable, validated methods of sterilization and/or reesterilization for all devices.

99N-4491

C 123

A listing of most commonly reprocessed devices has been included with guidance documents. The FDA asserts that those SUD's not on the list are automatically categorized as high risk. Does this mean that a plastic, sterile connector labeled single-use is high risk? In our opinion, FDA should remove this statement from its guidance. The FDA should provide a rationale for each device categorized as high risk. All the answers to the questions posed in the flowcharts, as well as all supporting documentation used in established and timely process set out for adding this evidence to the record and potentially changing the risk categorization of a SUD. The final guidance document should not be released until this multi-disciplinary panel can be identified to determine the final list of SUDs and their risk category.

The moderate category serves only to complicate an already complicated scheme. We would recommend the FDA consider only two device categories- low and high risk devices. The FDA needs to be decisive about the safety and risks associated with the reprocessing of every SUD.

As far as device categorization as low risk, by definition, the reprocessing of low risk devices does not present a risk to public health. As such, hospitals who engage in the reprocessing of low risk SUDs should be exempt from all pre-market notification and approval requirements. To ensure that reprocessing of low risk devices is safe and effective, decontamination, assembly and sterilization standards or recommended practices should be disseminated to hospitals. The American Society for Healthcare Central Service Professionals (ASHCSP) has developed recommended practices on all facets of reprocessing which could serve as a community best practices model.

With respect to high risk devices, facilities who will be unable to comply with the proposed guidelines should seek a commercial reprocessor for reprocessing of SUDs. Those facilities capable of complying, should be allowed to continue to engage in this activity.

As outlined in the Safe Medical Devices Act, hospitals are currently subject to reporting requirements as a device user. Requiring hospitals to comply with manufacturers, reporting requirements would be redundant and an inefficient use of already limited resources. Hospitals would benefit from further education and communication on the Act not a duplicative process for reporting adverse events.

Should the FDA proceed with enforcing all pre-market and notification requirements on hospitals, it is highly probable hospitals will elect to discontinue internal reprocessing activity. The investment of resources necessary to comply with pre-market and 510(k) application requirements would diminish any cost savings hospitals would realize by reprocessing single-use devices. We believe this would be an unfortunate outcome that would only serve to increase the cost of healthcare in hospitals without significantly adding to the already safe and effective reprocessing activity in which hospitals are currently engaged.

Respectfully submitted,

Robin Modder R.N. CNOR
Clinical Coordinator Surgical Services and OPC

Shari Lyons RN, BSN, CIC
Infection Control Coordinator

Mendocino Coast District Hospital
700 River Drive
Fort Bragg, Ca. 95437

700 Rm 1110r
Fort Bragg, CA
95437



Dockets Management Branch (HFA-305)
Division of Management Systems: Policy
Office of Human Resources &
Management Services
Food & Drug Administration
5603 Fishers Lane, Rm 1061
Rockville, MD 20852

20852/9999 